President Trump is preparing an executive order that would slash prices on nearly all drugs sold to Medicare; Allergan has recalled certain breast implants following 573 cases of implant-associated anaplastic large cell lymphoma; a study has found 1 in 4 people intend to use antibiotics without a prescription.
President Trump is preparing an executive order that would cut prices on nearly all prescription drugs sold to Medicare and other government programs. The measure would be broader than the administration’s previous proposal to lower drug costs by tying Part B drug prices to what other countries pay, 2 industry sources told Reuters. The administration is said to now be looking at similar methods to lower prices in Part D. While the White House and HHS declined to comment, the sources also told Reuters that Trump is also considering extending price controls to the Department of Defense, which oversees the Tricare health plan and the Department of Veterans Affairs.Allergan has recalled certain textured breast implants linked to a rare cancer following the FDA’s call for the manufacturer to do so. The decision comes 2 months after the FDA said there was not enough data to ban the sale of the breast implants. There have now been 573 cases of implant-associated anaplastic large-cell lymphoma and 33 related deaths, which is up significantly from the 457 cases and 9 deaths known in February. According to The Wall Street Journal, the FDA has attributed approximately 84% of the 573 cases to Allergan’s implants. While the implants represent a small portion of implants sold in the United States, the risk associated with them is about 6 times the risk of implants from other manufacturers. A study published in Annals of Internal Medicine is highlighting the prevalence of use of antibiotics without a prescription, which could increase unnecessary and inappropriate drug use or doses. It could also increase the risk of antimicrobial resistance, which is a growing public health crisis. The researchers drew on data from 31 previously published studies, finding that 1 in 4 people had intended to use antibiotics without a prescription. Meanwhile up to nearly half (48%) reported storing antibiotics for future use. The antibiotics were obtained without a prescription from a variety of sources, including previously prescribed doses, local markets or stores, and family or friends.
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Covered Preventive Services at Risk: V-BID Summit Breaks Down the Braidwood v Becerra Case
March 20th 2024For more than a decade, certain high-value preventive care services have been covered at no cost to patients under the Affordable Care Act, but a current legal challenge has the coverage at risk.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Most private health insurers have yet to publish criteria for when they will cover postpartum depression drug, zuranolone; state lawmakers are increasingly opposing health care mergers that they believe do not serve the public interest; Medicaid extensions made in 2021 led to a 40% decline in postpartum lack of insurance.
Read More
Zanubrutinib Plus Obinutuzumab Granted Accelerated FDA Approval for R/R Follicular Lymphoma
March 7th 2024The FDA granted accelerated approval to combination zanubrutinib and obinutuzumab for the treatment of relapsed or refractory (R/R) follicular lymphoma following 2 or more lines of therapy.
Read More